

# Emily Z Keung

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6598853/publications.pdf>

Version: 2024-02-01

47  
papers

4,199  
citations

361413

20  
h-index

243625

44  
g-index

49  
all docs

49  
docs citations

49  
times ranked

6110  
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>Realâ€world</scp> use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. International Journal of Cancer, 2022, 150, 2012-2024.	5.1	8
2	Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. Annals of Surgical Oncology, 2022, 29, 4376-4385.	1.5	12
3	Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020. Practical Radiation Oncology, 2022, 12, 437-445.	2.1	5
4	ASO Visual Abstract: Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. Annals of Surgical Oncology, 2022, , 1.	1.5	0
5	Utilization and evolving prescribing practice of opioid and nonâ€opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. Journal of Surgical Oncology, 2022, 125, 719-729.	1.7	1
6	Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. Journal of Investigative Dermatology, 2022, 142, 2046-2049.e3.	0.7	8
7	Sentinel Lymph Node Biopsy and Formal Lymphadenectomy for Soft Tissue Sarcoma: A Single Center Experience of 86 Consecutive Cases. Annals of Surgical Oncology, 2022, 29, 7092-7100.	1.5	8
8	ASO Author Reflections: Lymph Node Disease in Soft Tissue Sarcoma: A Problematic Clinical Dilemma. Annals of Surgical Oncology, 2022, , 1.	1.5	1
9	Management of Skin Sarcomas. Surgical Oncology Clinics of North America, 2022, 31, 511-525.	1.5	2
10	Evaluating the Impact of Surveillance Follow-Up Intervals in Patients Following Resection of Primary Well-Differentiated Liposarcoma of the Retroperitoneum. Annals of Surgical Oncology, 2021, 28, 570-575.	1.5	4
11	Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVIDâ€19 pandemic: A guide for surgical oncologists. Journal of Surgical Oncology, 2021, 123, 12-23.	1.7	7
12	Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Network Open, 2021, 4, e210945.	5.9	66
13	Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Annals of Surgical Oncology, 2021, 28, 3480-3489.	1.5	7
14	Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathologica, 2021, 142, 565-590.	7.7	12
15	Disseminated Coccidioidomycosis Following COVID-19 Mimicking Metastatic Thoracic Relapse of Well-Differentiated Liposarcoma: A Case Report. Frontiers in Medicine, 2021, 8, 715939.	2.6	6
16	Identification of MicroRNAâ€mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers, 2021, 13, 5301.	3.7	7
17	Postoperative pancreatic fistula after distal pancreatectomy for non-pancreas retroperitoneal tumor resection. American Journal of Surgery, 2020, 220, 140-146.	1.8	9
18	Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. Cell Reports, 2020, 33, 108293.	6.4	39

#	ARTICLE	IF	CITATIONS
19	Surgical decision-making and prioritization for cancer patients at the onset of the COVID-19 pandemic: A multidisciplinary approach. <i>Surgical Oncology</i> , 2020, 34, 182-185.	1.6	19
20	ASO Author Reflections: Surveillance After Resection of Retroperitoneal Well-Differentiated Liposarcoma: A Balancing Act Between Earlier Recurrence Detection, Patient Anxiety, and Health Care Resource Expenditure. <i>Annals of Surgical Oncology</i> , 2020, 27, 748-749.	1.5	0
21	Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. <i>Journal of the National Cancer Institute</i> , 2020, 112, 875-885.	6.3	20
22	B cells are associated with survival and immunotherapy response in sarcoma. <i>Nature</i> , 2020, 577, 556-560.	27.8	1,158
23	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	27.8	1,421
24	Correlative Analyses of the SARCO28 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. <i>Clinical Cancer Research</i> , 2020, 26, 1258-1266.	7.0	115
25	The degree of sclerosis is associated with prognosis in well-differentiated liposarcoma of the retroperitoneum. <i>Journal of Surgical Oncology</i> , 2019, 120, 382-388.	1.7	5
26	The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 369-386.	1.5	19
27	Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22246-22251.	7.1	142
28	Window-of-Opportunity Trials: The Road Forward in Soft Tissue Sarcoma and Beyond. <i>Annals of Surgical Oncology</i> , 2019, 26, 1188-1189.	1.5	0
29	The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. <i>Annals of Surgical Oncology</i> , 2018, 25, 1814-1827.	1.5	45
30	The clinical behavior of well differentiated liposarcoma can be extremely variable: A retrospective cohort study at a major sarcoma center. <i>Journal of Surgical Oncology</i> , 2018, 117, 1799-1805.	1.7	7
31	Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. <i>Oncolmmunology</i> , 2018, 7, e1385689.	4.6	46
32	Defining the incidence and clinical significance of lymph node metastasis in soft tissue sarcoma. <i>European Journal of Surgical Oncology</i> , 2018, 44, 170-177.	1.0	82
33	Accurate and Reproducible Diagnosis of Canine Soft Tissue Sarcoma Using Mass Spectrometry: A Step in the Right Direction. <i>Cancer Cell</i> , 2018, 34, 697-699.	16.8	2
34	Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. <i>BMC Cancer</i> , 2018, 18, 913.	2.6	69
35	Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma. <i>Cancer</i> , 2018, 124, 4495-4503.	4.1	100
36	Engineered T Cells in Synovial Sarcoma: Persistence Pays Off!. <i>Cancer Discovery</i> , 2018, 8, 914-917.	9.4	3

#	ARTICLE	IF	CITATIONS
37	The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 775-784.	2.4	268
38	Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression. <i>Cell Reports</i> , 2017, 19, 875-889.	6.4	78
39	Management of Gastrointestinal Stromal Tumors. <i>Surgical Clinics of North America</i> , 2017, 97, 437-452.	1.5	35
40	H3K9me3-mediated repression of KLF6: Discovering a novel tumor suppressor in liposarcoma using a systematic epigenomic approach. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1093691.	0.7	2
41	Surgical Management of Metastatic Disease. <i>Surgical Clinics of North America</i> , 2016, 96, 1175-1192.	1.5	10
42	The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors. <i>Current Treatment Options in Oncology</i> , 2016, 17, 8.	3.0	27
43	Dual Roles of RNF2 in Melanoma Progression. <i>Cancer Discovery</i> , 2015, 5, 1314-1327.	9.4	57
44	Predictors of Outcomes in Patients with Primary Retroperitoneal Dedifferentiated Liposarcoma Undergoing Surgery. <i>Journal of the American College of Surgeons</i> , 2014, 218, 206-217.	0.5	99
45	Immunocompromised Status in Patients With Necrotizing Soft-Tissue Infection. <i>JAMA Surgery</i> , 2013, 148, 419.	4.3	68
46	Concise Review: Genetically Engineered Stem Cell Therapy Targeting Angiogenesis and Tumor Stroma in Gastrointestinal Malignancy. <i>Stem Cells</i> , 2013, 31, 227-235.	3.2	45
47	In-Hospital and Long-Term Outcomes after Percutaneous Endoscopic Gastrostomy in Patients with Malignancy. <i>Journal of the American College of Surgeons</i> , 2012, 215, 777-786.	0.5	53